CNS Cancer: Models, Markers, Prognostic Factors, Targets, and Therapeutic ApproachesErwin G. Van Meir Springer Science & Business Media, 15 aug 2009 - 1284 pagina's Cancers of the central nervous system are among the most lethal of human neoplasms. They are recalcitrant to even intensive multimodality therapies that include surgery, radiotherapy, and chemotherapy. Moreover, especially in children, the consequences of these therapies can itself be devastating and involve serious cognitive and developmental disorders. It is small wonder that such cancers have come under the intense scrutiny of each of the subspecialties of clinical care and investigation as well as attracting some of the best basic research scientists. Their joint efforts are gradually peeling away the mysteries surrounding the genesis and progression of these tumors and inroads are being steadily made into understanding why they resist therapies. This makes it an especially opportune time to assemble some of the best investigators in the field to review the ‘‘state of the art’’ in the various arenas that comprise the assault on CNS tumors. The breadth of this effort by the clinical and basic neuro-oncology community is quite simply amazing. To a large extent, it evolves from the knowledge of the human genome and its regulation that has been hard won over the past two decades. |
Inhoudsopgave
3 | |
29 | |
44 | |
61 | |
PtenDeficient Mouse Models for HighGrade Astrocytomas | 77 |
Dissecting Genetic Susceptibility to Brain Cancer | 93 |
Implications for Preclinical Cancer Drug Development | 119 |
Human Brain Tumor Cell and Tumor Tissue Transplantation Models | 146 |
MicroRNAs in the Central Nervous System and Potential Roles of RNA Interference in Brain Tumors | 651 |
Understanding Glioma Resistance to Temozolomide Therapy | 679 |
Brain Tumor Stem Cell Markers | 712 |
Therapeutic Targets and Targeting Approaches | 729 |
Clinical Agents for the Targeting of Brain Tumor Vasculature | 731 |
Bone MarrowDerived Cells in GBM Neovascularization | 748 |
Vascular Targeting of Brain Tumors Bridging the Gap with Phage Display | 775 |
Impact of the BloodBrain Barrier on Brain Tumor Imaging and Therapy | 788 |
Transformed Human Brain Cells in Culture as a Model for Brain Tumors | 163 |
Rat Glioma Models for Preclinical Evaluation of Novel Therapeutic and Diagnostic Modalities | 181 |
Neurooncogenesis Induced by Nitroso Compounds in Rodents and StrainSpecific Genetic Modifiers of Predisposition | 206 |
The Murine GL261 Glioma Experimental Model to Assess Novel Brain Tumor Treatments | 227 |
Opportunities as Preclinical Model Systems | 243 |
Prognostic Factors and Biomarkers | 281 |
p53 Pathway Alterations in Brain Tumors | 282 |
The PTENPI3 Kinase Pathway in Human Glioma | 315 |
Value of 1p19q and Other LOH Markers for Brain Tumor Diagnosis Prognosis and Therapy | 359 |
Discovery of Genetic Markers for Brain Tumors by Comparative Genomic Hybridization | 373 |
Genomic Identification of Significant Targets in Brain Cancer | 395 |
Oncomodulatory Role of the Human Cytomegalovirus in Glioblastoma | 414 |
Aberrant EGFR Signaling in Glioma | 441 |
Mechanisms of Brain Tumor Angiogenesis | 461 |
The Role of Thrombosis and Tissue Factor | 507 |
Tumor Biology and Treatment Stratification | 529 |
Proteomic Profiling of Human Brain Tumors | 552 |
Proteomic Discovery of Biomarkers in the Cerebrospinal Fluid of Brain Tumor Patients | 577 |
Epigenetic Profiling of Gliomas | 614 |
Targeting CXCR4 in Brain Tumors | 813 |
Molecular Targeting of IL13Ralpha2 and EphA2 Receptor in GBM | 846 |
Molecular Targets for AntibodyMediated Immunotherapy of Malignant Glioma | 865 |
Stat3 Oncogenic Signaling in Glioblastoma Multiforme | 899 |
Inhibition of Ras Signaling for Brain Tumor Therapy | 919 |
HGFcMet Signaling and Targeted Therapeutics in Brain Tumors | 933 |
Combinatorial Therapeutic Strategies for Blocking Kinase Pathways in Brain Tumors | 953 |
Targeting of TRAIL Apoptotic Pathways for Glioblastoma Therapies | 976 |
Implications for Apoptotic and Inflammatory Responses and Exploitation for Therapy | 1011 |
Targeting Endoplasmic Reticulum Stress for Malignant Glioma Therapy | 1037 |
Brain Cancer Stem Cells as Targets of Novel Therapies | 1057 |
The Use of Retinoids as Differentiation Agents Against Medulloblastoma | 1076 |
Herpes Simplex Virus 1 HSV1 for Glioblastoma Multiforme Therapy | 1105 |
The Development of Targeted Cancer GeneTherapy Adenoviruses for HighGrade Glioma Treatment | 1137 |
Harnessing TCell Immunity to Target Brain Tumors | 1165 |
Mechanisms and Therapeutic Challenges | 1219 |
1253 | |
Overige edities - Alles bekijken
CNS Cancer: Models, Markers, Prognostic Factors, Targets, and Therapeutic ... Erwin G. Van Meir Geen voorbeeld beschikbaar - 2009 |
Veelvoorkomende woorden en zinsdelen
Acad Sci USA activation analysis angiogenesis angiopoietin-2 antibody apoptosis astrocytes astrocytomas Bigner Biol biological brain tumors Cancer Cell Cancer Res cell cycle cell lines cellular chemokine chromosome Clin clinical Color Plate CXCR4 differentiation DNA methylation drug EGFR endothelial cells endothelial growth factor epidermal growth factor epigenetic function gene expression genetic genomic glial glioblastoma multiforme glioma cells grade growth factor receptor HCMV human GBM human glioma identified induced infection inhibition inhibitor invasion kinase malignant glioma markers medulloblastoma methylation mice microarray microRNA miRNAs molecular mouse models murine mutations Natl Acad Sci nervous system neural normal Oncogene Oncol overexpression patients PDGF phosphorylation PI3K Proc Natl Acad profiling progenitor proliferation promoter protein proteomic PTEN regulation role specific Stat3 studies survival target temozolomide therapeutic therapy tissue transcription transgenic tumor cells tumor suppressor tumor suppressor genes tyrosine vascular endothelial growth VEGF vitro vivo Wang Zhang